Try our corporate solution for free!

Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020

Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*

Exclusive Premium statistic

You need a Statista Account for unlimited access.

  • Full access to 1m statistics
  • Incl. source references
  • Available to download in PNG, PDF, XLS format
Statista Accounts

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Use Ask Statista Research Service

Release date

May 2018


United States

Survey time period

as of December 2015

Number of respondents

228 respondents

Special properties

executives involved in health care industry

Supplementary notes

* Executives at medical practices, hospitals, large healthcare systems, benefit management organizations, health plans, long-term care organizations, group purchasing organizations and consulting firms.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on " Generics and biosimilars "

Statistics on Generics and biosimilars

Global overview


Top companies


U.S. market


Patent expiration






Further related statistics

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.